Efficacy and safety of diacerein in the treatment of patients with

Efficacy and safety of diacerein in the treatment of patients with diacerein For the treatment of symptoms associated with degenerative diseases of the joints, Diacerein 50 mg is the first choice This brand-name drug is slow acting diacerein Diacerein was obtained by diacetylation of an anthraquinone derivative rhein and was approved by FDA in 2008, in the treatment of osteoarthritis due

diacerein Diacerein is in a class of substances called anthraquinones A slow-acting drug, it is intended to block actions of interleukin 1 beta protein,

diacerein Request PDF Studies on the preparation, characterization and solubility of β-cyclodextrin -diacerein inclusion complexes Diacerein is a symptomatic slow-acting drug in osteoarthritis with anti-inflammatory, anti-catabolic and pro-anabolic properties